Search PubMed⌕ Search

Biomedical subjects

J Crouzet

Publications and source records attributed to J Crouzet.

At least 91 records · Page 5Linked to original sources
PubMed1988

[Fibroblastic rheumatism. A clinical and histological entity].

In 1980 was described for the first time a disease which seemed unknown until then. From that time three cases have been published. The current study summarizes their common characteristic, combining joint involvements to nodular-type involvements to systemic involvement, i.e. a specific histology. This entity has been named fibroblastic rheumatism. Nosologically, it is situated between juvenile fibroblastoses without joint involvement and with nodules, and adult sclerodermis with joint and systemic involvement without nodules.

Adult↗
PubMed1987

[Spontaneous fissures and fractures of the legs in patients with osteoporosis treated with sodium fluoride].

Thirteen cases of spontaneous fissure or fracture of the lower limbs observed in 8 patients under treatment with sodium fluoride are reported; 7 of these patients were being treated for osteoporosis. The fissures occurred after 20 months of treatment on average and were revealed by pain in the metaphysis with early high radionuclide uptake. Three to 4 weeks later, X-ray films showed a linear bone condensation area, involving in most cases, the tibial metaphysis, the femoral neck and the calcaneum. The prognosis was usually favourable, but 2 patients required surgery for fissure of the femoral neck with rupture of the cortex. Fluor seems to be responsible for the fissures which cannot be avoided by calcium and/or vitamin D intake. The main pathogenic hypotheses are excessive bone resorption, large amounts of poorly mineralized osteoid tissue and architectural abnormalities of the trabeculae. When such fissures occur, fluoride therapy must be discontinued and the limb put at rest, but since this side-effect is rare and usually benign the principle of a treatment that is beneficial in many cases of osteoporosis need not be revised.

Aged↗
PubMed1986

[Pyrithioxin and rheumatoid polyarthritis].

After reviewing the literature, the authors demonstrate that pyrithioxine is active in rheumatoid arthritis. The effectiveness is marked by a 50 per cent reduction in the articular index in 59.7 per cent of cases, a reduction in the duration of morning stiffness in 49 per cent of cases, a decreased erythrocyte sedimentation rate in 52.4 per cent of cases and a statistically significant decrease in the mean of these parameters in relation to the mean value at the beginning of treatment. The good results were considered to be those cases in which two of the three criteria (articular index, morning stiffness and erythrocyte sedimentation rate) were decreased by at least 50 per cent. Secondary escapes from treatment (13 per cent) and suspension of treatment for intolerance were considered to represent treatment failures. A good result was obtained in 42.7 per cent of cases. Side effects were observed in 40.1 per cent of cases and were responsible for suspension of treatment in 22.8 per cent of cases. Half of the side effects consisted of muco-cutaneous reactions which generally appeared early and were benign. Haematological, renal and gastrointestinal effects and aguestia occurred more rarely. However, a number of patients died as a result of agranulocytosis, hepatitis or extramembranous glomerulonephritis.

Agranulocytosis↗
PubMed1983

[Sterno-costo-clavicular hyperostosis. Apropos of a case. Review of the literature].

The authors report a case of sterno-costo-clavicular hyperostosis. Since Kohler's first description in 1975, 15 observations have already been reported. The disease consists in a painful swelling of the clavicles, sternum and upper anterior ribs. On roentgenograms these bones are enlarged and show increased density. Bone scan shows markedly increased uptake. Phlebography shows subclavian vein occlusions. Histological examination demonstrates hyperostosis without osteoclasis as in Paget disease.

Bone Diseases, Developmental↗
PubMed1982

[Treatment of extra-articular rheumatism with pirprofen].

The efficacy and tolerance of pirprofen in the treatment of extra-articular rheumatisms were studied in 3 double-blind trials which included a total of 227 patients. The first study was conducted in a medical center for sports injuries and compared a daily dose of 800 mg of pirprofen to a placebo over 7 days on 58 patients. By the third day, pirprofen was judged by doctors to be of good or excellent efficacy in 79% of patients, as compared to 24% on placebo (p less than 0,01). After 7 days, the results were confirmed with 63% of good and excellent efficacy in the pirprofen group versus 12% for the placebo (p less than 0,001). The two other studies compared pirprofen (800 mg/day) to ketoprofen (300 mg/day). One of the trials was conducted in a medical center for sports injuries on 79 patients. After 7 days of treatment, improvement was noted in 58 to 80% of the patients. The better results observed in sports medicine as compared to the traditional rheumatological diseases is due to the difference in the recruitment of the patients. In both trials, the 2 active drugs had a clear, comparable efficacy. Side effects were rare: primarily gastralgia which were more frequent amongst patients treated by pirprofen (11 out of 25) than those on placebo (4 out of 26). In trials comparing pirprofen and ketoprofen, side effects, especially gastralgia were noted in 30% of the patients in each group. 14 patients treated by pirprofen and 10 patients treated by ketoprofen interrupted treatment for side effects.

Adult↗
PubMed1982

[Hypophosphoremic osteomalacia of connective tissue tumors].

The authors undertake a general review of the association between hypophosphoraemia and connective tissue tumour, based upon three personal cases and 27 cases of benign connective tissue tumours, as well as cases of hypophosphoraemia related to malignant tumours or to diffuse dysplasia of connective tissue origin, collected from the literature. This syndrome is distinguished from hypophosphoraemia induced by other tumours (myeloma, carcinoma of the prostate) which are based upon different mechanisms. Hypophosphoraemia, associated with a fall in plasma levels of 1-25 (OH)2 D3 by inhibition of renal 1 alpha hydroxylase, suggests the existence of a complex tubular deficit. Removal of the tumour, most often vascular and intra- or para-osseous, results in rapid normalisation of laboratory then radiological and clinical abnormalities. The physiopathology of the syndrome remains very mysterious. It may be likened to certain tubulotoxic syndromes due to cadmium and in particular to maleic acid. However no precise data yet exists regarding any possible abnormal tumour secretion. In practice, any case of hypophosphoraemic osteomalacia requires investigation to locate a possible tumour of connective tissue, and this all the more so when it is accompanied by very low plasma levels of 1-25(OH)2 D2.

Adolescent↗